Cells of the osteoblast lineage affect the homing 1,2 and the number of long-term repopulating haematopoietic stem cells 3,4 , haematopoietic stem cell mobilization and lineage determination and B cell lymphopoiesis [5] [6] [7] . Osteoblasts were recently implicated in pre-leukaemic conditions in mice 8, 9 . However, a single genetic change in osteoblasts that can induce leukaemogenesis has not been shown. Here we show that an activating mutation of b-catenin in mouse osteoblasts alters the differentiation potential of myeloid and lymphoid progenitors leading to development of acute myeloid leukaemia with common chromosomal aberrations and cell autonomous progression. Activated b-catenin stimulates expression of the Notch ligand jagged 1 in osteoblasts. Subsequent activation of Notch signalling in haematopoietic stem cell progenitors induces the malignant changes. Genetic or pharmacological inhibition of Notch signalling ameliorates acute myeloid leukaemia and demonstrates the pathogenic role of the Notch pathway. In 38% of patients with myelodysplastic syndromes or acute myeloid leukaemia, increased b-catenin signalling and nuclear accumulation was identified in osteoblasts and these patients showed increased Notch signalling in haematopoietic cells. These findings demonstrate that genetic alterations in osteoblasts can induce acute myeloid leukaemia, identify molecular signals leading to this transformation and suggest a potential novel pharmacotherapeutic approach to acute myeloid leukaemia.
Mice expressing a constitutively active b-catenin allele in osteoblasts, referred to here as Ctnnb1 CAosb (CA, constitutively active; osb, osteoblast specific constitutive activity) are osteopetrotic 10 , and die before 6 weeks of age ( Fig. 1a ) for unknown reasons. Upon further examination, Ctnnb1 CAosb mice were anaemic at 2 weeks of age with peripheral blood monocytosis, neutrophilia, lymphocytopenia and thrombocytopenia (Extended Data Fig. 1a ). Erythroid cells were decreased in the marrow and extramedullary haematopoiesis was observed in the liver ( Fig. 1c and Extended Data Fig. 1b, l, m) . Although the number of myeloid (CD11b 1 /Gr1 1 ) cells decreased due to osteopetrosis, their relative percentage increased, indicating a shift in the differentiation of HSCs to the myeloid lineage ( Fig. 1d and Extended Data Fig. 1c, d) . The haematopoietic stem and progenitor cell (HSPC) population in the bone marrow (Lin 2 Sca 1 c-Kit 1 , LSK) cells decreased twofold in Ctnnb1 CAosb mice, but their percentage was twofold greater than in wild-type littermates ( Fig. 1e and Extended Data Fig. 1e, f) . The long-term repopulating HSC progenitors (LT-HSCs) increased in numbers and percentage, whereas the lymphoid-biased multipotential progenitors, LSK 1 /FLT3 1 , and the granulocyte/monocyte progenitors (GMP) (Extended Data Fig. 1g -j) decreased. The GMP percentage increased (Fig. 1f) . Identical abnormalities were observed in the spleen of Ctnnb1 CAosb mice (Extended Data Fig. 1n-p) . The mutation was introduced in osteoblasts but not in any cells of the haematopoietic compartment (Extended Data Fig. 1q -t) of Ctnnb1 CAosb mice.
Blasts (12-90%) and dysplastic neutrophils (13-81%) were noted in the blood and there was dense and diffuse infiltration with myeloid and monocytic cells, blasts (30-53% for n 5 12 mice) and dysplastic neutrophils in the marrow and spleen of Ctnnb1 CAosb mice ( Fig. 1g -k, Extended Data Fig. 2a-c ). In the liver, clusters of immature cells with atypical nuclear appearance were seen (Fig. 1l ). The increase in immature myeloid cells was confirmed by staining with myeloid markers in bones, spleen and liver (Extended Data Fig. 2d -h). Reduced B-cell lymphopoiesis without changes in T-cell populations was observed in Ctnnb1 CAosb mice (Extended Data Fig. 2i -t). Differentiation blockade was demonstrated by the presence of immature myeloid progenitors in Ctnnb1 CAosb marrow and differentiation cultures (Fig. 1m , n and Extended Data Fig. 2u-x) . These cellular abnormalities fulfil the criteria of AML diagnosis in mice 11 with principle features of human AML 12,13 .
A clonal abnormality involving a Robertsonian translocation Rb(1;19) was identified in myeloid cells of the spleen of a Ctnnb1 CAosb mouse (Extended Data Fig. 2y ). Recurrent numerical and structural chromosomal alterations were also detected in myeloid cells of the spleen of all mutant mice examined ( Fig. 2a and Extended Data Table 1 ). Frequent abnormalities were detected in chromosome 5, the mouse orthologue of human chromosome 7q associated with common cytogenetic abnormalities in patients with myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) 14 . Whole-exome sequencing identified 4 non-silent somatic mutations in myeloid cells from 3 Ctnnb1 CAosb mice ( Fig. 2b and Extended Data Fig. 2z ), including a recurrent one in Tnfrsf21 and a single somatic mutation in Crb1 previously reported in human AML 15 , but sample size has insufficient statistical power to determine if it is a driver or passenger mutation. Hence, constitutive activation of b-catenin in osteoblasts facilitates clonal progression and is associated with somatic mutations in myeloid progenitors.
Transplantation of bone marrow cells from Ctnnb1 CAosb leukaemic mice into lethally irradiated wild-type recipients induced all features of haematopoietic dysfunction and AML observed in Ctnnb1 CAosb mice including blasts (15-80%) and dysplastic neutrophils (15-75%) in the blood and blasts (30-40%) and abnormal megakaryocytes in the marrow and early lethality (Extended Data Fig. 3a -i). Transplantation of wild-type bone marrow cells to lethally irradiated Ctnnb1 CAosb mice also resulted in AML with early lethality (Extended Data Fig. 3j -r). Transplantation of LT-HSCs, but not other haematopoietic populations, from Ctnnb1 CAosb mice to sub-lethally irradiated wild-type recipients resulted in AML with early lethality (Fig. 2c, d and Extended Data Fig. 3s -z) indicating that LT-HSCs are the leukaemia-initiating cells (LICs). These results demonstrate that osteoblasts are the cells responsible for AML development in this model. Remarkably, HSCs of Ctnnb1 CAosb mice have acquired a permanent self-perpetuating genetic alteration that becomes independent of the initial mutation in osteoblasts.
All Ctnnb1 CAosb mice examined develop AML between 2 (40%) and 3.5 (60%) weeks of age. Livers of Ctnnb1 CAosb newborn mice show increased LSK cells and cells of the myeloid lineage, and a decrease in erythroid and B-lymphoid cells (Extended Data Fig. 4a -j). Microhypolobated megakaryocytes, Pelger Huet neutrophils, seen in MDS and other congenital entities, and nuclear cytoplasmic asynchrony in the erythroid lineage were also seen in the liver and bone marrow of newborn Ctnnb1 CAosb mice, while their spleens showed increased number of blasts and a shift towards the myeloid lineage (Extended Data Fig. 4k -m). 2 10 12 showing areas of genetic gain (red bars) and loss (green bars) identified by aCGH in Ctnnb1 CAosb mice. n 5 5. b, Sequence traces of somatic mutations in myeloid malignancies (CD11b 1 /Gr1 1 ) from 3 Ctnnb1 CAosb mice. c, Blasts (12-75%, solid arrows) in blood of sub-lethally irradiated CD45.1 wild-type mice transplanted with LT-HSCs from CD45.2 Ctnnb1 CAosb mice, 4 weeks following transplantation. d, Lethality in wild-type mice transplanted with indicated haematopoietic populations from Ctnnb1 CAosb mice. n 5 7. Results are representative of two independent experiments.
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These characteristics indicate deregulated haematopoiesis with neutrophil dyspoiesis at birth. Less than 20% blasts were seen in the marrow, consistent with a diagnosis of MDS with excess blasts (RAEB1/2). Differentiation blockade was not observed in newborn animals and fetal HSCs did not transfer the disease (Extended Data Fig. 4n -w) due to lack of HSC-osteoblast interaction in the fetal liver. These results confirm that AML is induced by defective niche signals that are restricted to the bone marrow osteoblasts.
b-catenin target genes in osteoblasts that may regulate HSC fate were identified by microarray analysis. One gene, the Notch ligand jagged 1, fulfilled 4 criteria: (1) acts on adjacent cells; (2) activates a pathway of which many targets are increased in the array; (3) has been implicated in haematopoiesis; and (4) is regulated transcriptionally by b-catenin (Extended Data Fig. 5a-d and ref. 16 ). Accordingly, jagged 1 expression was increased in Ctnnb1 CAosb bones and expression of the Notch targets Hes1, Hes5, Hey1, Hey2 increased and Hes1 targets Cebpa (also known as Cebpa) and Spi1 (also known as Pu.1) decreased in Ctnnb1 CAosb LSK cells of Ctnnb1 CAosb mice, indicating increased Notch signalling in this population (Fig. 3a, b and Extended Data Fig. 5a , b, f, g). Notch1 and Notch2 expression was not affected (Extended Data Fig. 5e ). Increased Notch signalling occurred specifically in the leukaemia-initiating LT-HSCs without changes in the other LSK compartments (Extended Data Fig. 5f , g).
To determine if jagged 1 in osteoblasts contributes to AML development in Ctnnb1 CAosb mice, we removed one allele of jagged 1 in osteoblasts (Ctnnb1 CAosb ;Jag1 osb 1/2 mice). These genetic manipulations decreased Notch signalling is LSK cells, rescued anaemia and deregulation of HSC lineage differentiation and prevented AML development ( Fig. 3d -f, Extended Data Fig. 6a -j). Ctnnb1 CAosb ;Jag1 osb 1/2 mice survived and were healthy for the entire time they were observed, even though they remained osteopetrotic ( Fig. 3g and Extended Data Fig. 6k ). Similarly, pharmacological inhibition of Notch signalling with a csecretase inhibitor 17 reversed haematopoietic deregulation and myeloid expansion in blood, marrow and spleen and reversed AML in Ctnnb1 CAosb mice without affecting osteopetrosis (Extended Data Figs 5h-s and 7), indicating that osteopetrosis is not enough to drive AML. These observations suggest that Notch signalling is required for AML development in Ctnnb1 CAosb mice and that chromosomal alterations may result from increased Notch signalling 18 . Alternatively, healthy HSCs in the endothelial and perivascular niche can multiply and outgrow leukaemic HSCs in DBZ-treated Ctnnb1 CAosb mice. The gene jagged 1 is required for leukaemia induction; whether it is involved in leukaemia maintenance with a therapeutic benefit remains to be examined.
To assess the relevance of these findings to humans we examined activation of b-catenin signalling in bone marrow biopsies from MDS or AML patients. Forty-one out of 107 patients examined with all MDS subtypes, AML, or MDS that had transformed to AML (38.3%) showed nuclear localization of b-catenin in osteoblasts ( Fig. 4a, Table 1 ) but in none of the 56 healthy controls examined ( Fig. 4c and Extended Data Fig. 9a -g, i, j). Myeloid and erythroid cells and megakaryocytes in all patients and healthy control subjects showed membrane staining for b-catenin. Notch signalling was specifically activated only in patients with nuclear accumulation of b-catenin as indicated by HEY1 nuclear staining in their haematopoietic cells ( Fig. 4d and Extended Data Fig. 8a-f ). Expression of all examined b-catenin target genes and JAG1 and DLL1 was upregulated over twofold in osteoblasts from MDS/AML patients with b-catenin nuclear accumulation in osteoblasts ( Fig. 4h , i) but not in healthy controls. Notch activity was increased in haematopoietic cells from the same patients, but not healthy controls, as indicated by twofold increase in the expression of Notch transcriptional targets ( Fig. 4j ). It is possible that aberrant b-catenin signalling in osteoblasts of these patients may be the consequence of haematopoietic clones altering expansion or functionality of different stromal cell lineages, as recently reported 19 . During screening of assumed healthy controls, two individuals had nuclear b-catenin in osteoblasts. Re-evaluation showed that one patient developed MDS and the second an underlying MPN/MDS, a pre-AML condition with features of both a myeloproliferative neoplasm (MPN) and MDS (Extended Data Fig. 8g , h) suggesting a potential prognostic value.
b, Extended Data Figs 8a-h and 9h and Supplementary
Notch activation promotes expansion of myeloid cells 20 and acute megakaryoblastic leukaemia-like disease in mice 21 . Other studies show that the Notch pathway may act as tumour suppressor in AML 22-24 . However, in these models, LICs are found in GMPs, whereas in our model LICs are in LT-HSCs, suggesting that different LICs can have distinct consequences. Additionally, increased mammalian jagged 1 expression may not elicit identical outcomes as increased Notch signalling by all Notch receptors [25] [26] [27] and Ctnnb1 CAosb osteoblasts may stimulate additional signals that act in combination with Notch to induce mutations contributing to AML. Notch also has a role in T-cell acute lymphoblastic leukaemia (T-ALL) pathogenesis 28 , but T-cell-specific cooperative signals seem to be required to induce transformation 29 .
The idea that osteolineage cells can induce myeloid malignancies has been previously put forward 9 . Our observations that osteoblasts determine the appearance of cell-autonomous AML with 100% penetrance, and the molecular and genetic dissection of how this occurs in mice and humans, demonstrate the role of the marrow niche as a determinant of haematological disorders. This finding may also be informative 
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about MDS/AML pathogenesis in humans and expand the potential of new therapeutic applications.
METHODS SUMMARY
Mice. Generation of a1(I)Collagen-Cre, Catnb 1/lox(ex3) , Ctnnb1 CAosb and Jag1 fl/fl mice have previously been reported. The original nomenclature used for these mice was bcat(ex3)osb. Catnb 1/lox(ex3) mice express a b-catenin mutant allele in which exon 3, encoding all serine and threonine residues phosphorylated by glycogen synthase kinase 3b, is flanked by loxP sites. All the protocols and experiments were conducted according to the guidelines of the Institute of Comparative Medicine, Columbia University. 
AML patient-membrane β-catenin
Healthy subject-membrane β-catenin 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 10 1 10 2 10 3 10 4 10 5 Author Information Microarray and aCGH data were deposited in Gene Expression Omnibus (accession numbers GSE43242, GSE51690) and exome sequencing data were deposited in Sequence Read Archive (accession number SRP031981). Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to S.K. (sk2836@columbia.edu).
RESEARCH LETTER

METHODS
Animals. Generation of a1(I)Collagen-Cre and Catnb 1/lox(ex3) mice have previously been reported [30] [31] [32] . Catnb 1/lox(ex3) mice express a b-catenin mutant allele in which exon 3, encoding all serine and threonine residues phosphorylated by glycogen synthase kinase 3b (GSK-3b) 33 , is flanked by loxP sites. Mice with osteoblast-specific constitutive activation of b-catenin were generated by crossing Catnb 1/lox(ex3) mice with a 1 (I)Col-Cre mice expressing Cre under the control of 2.3 kb of the proximal promoter of the mouse pro-a1(I) collagen gene. The transgene is expressed at high levels in osteoblasts specifically 34 . There is no expression in chondrocytes, condensed mesenchymal cells, perichondrial or periosteal fibroblasts, or any other type I collagen-producing cells, or other fibroblast-rich tissues such as muscle, heart or tendons. The resulting offspring, termed Ctnnb1 CAosb (original nomenclature bcat(ex3) osb ), express a constitutively active b-catenin allele in osteoblasts. Mice with osteoblast-specific deletion of jagged 1 were generated by crossing previously described Jag1 fl/fl mice 35 with a 1 (I)Col-Cre mice. Genotyping was performed at weaning stage by PCR analysis of genomic DNA. In each experiment the mice used were all littermates of the same genetic background. Onemonth-old female mice were used for the bone histomorphometric analysis. Ctnnb1 CAosb mice lack teeth due to osteopetrosis and therefore were fed a normal powdered diet that contained all the required nutrients (20% protein, 3.0 p.p.m. folic acid, 51 mg per kg vitamin B12 from PicoLab Rodent Diet 20). Folate and vitamin B12 levels in their blood were normal (folate .24 ng ml 21 and B12 . 1,000 pg ml 21 ) confirming adequate intake of critical nutrients. Folate and vitamin B12 levels were measured by Antech Diagnostics using a chemiluminescence based kit (Siemens). All the protocols and experiments were conducted according to the guidelines of the Institute of Comparative Medicine, Columbia University. Randomization was done according to genotype and blinding was applied during histological analysis. Patient samples. Bone marrow biopsies from patients with AML and MDS were consecutively obtained from 2000 to 2008 and reviewed under a research exempt waiver approved by the institutional review board (IRB) of Memorial Sloan-Kettering Hospital and Human Biospecimen Utilization Committee. Bone marrow biopsies and aspirates obtained from Columbia University from patients with MDS and AML were stored in the IRB-approved Tissue Repository at Columbia University Medical Center after informed consent. This study was conducted under protocol approval from the IRB for use of samples from the Tissue Repository. Karyotype analysis. Metaphase chromosome preparations were prepared from cells obtained from spleen specimens from Ctnnb1 CAosb mice after overnight culture in complete RPMI medium using standard methods. Giemsa banding was performed and the images were captured using Cytovision Imaging system (Applied Imaging) attached to a Nikon Eclipse 600 microscope. Twenty to thirty karyotypes were prepared from each sample and described using the standard chromosome nomenclature for mice. Array comparative genomic hybridization (aCGH). aCGH analysis was performed in the spleen of Ctnnb1 CAosb mice using the mouse genome CGH 244A platform (Agilent Technologies) according to the manufacturer's instructions. In brief, spleen DNA from wild-type littermates was used as reference DNA. Genomic DNA was subjected to restriction digestion before labelling and purification (SureTag DNA labelling kit, Agilent Technologies). For each 244 K array, 2 mg of labelled DNA and 2 mg of germline reference DNA were labelled with Cy5 and Cy3, respectively. Differentially labelled test (tumour) DNA and normal reference DNA were hybridized simultaneously to normal chromosome spreads. Data extraction was conducted using the Agilent feature extraction software. Data files were analysed using the Agilent DNA analytics software. Data were deposited in Gene Expression Omnibus (accession number GSE51690). Whole-exome capture and massively parallel sequencing, sequence mapping and identification of tumour-specific variants. For three tumour and three unpaired normal samples, purified genomic DNA (3 mg) was enriched in proteincoding sequences using the SureSelect Mouse All Exon kit (Agilent Technologies) following standard protocols. The resulting target-enriched pool was amplified and subjected to paired-end sequencing (2 3 100 bp) by using HiSeq2000 sequencing instruments. Exome capture and sequencing procedures were performed at Agilent Technologies. Sequencing reads were mapped to the reference genome mm10 using the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9 (ref. 36) . We identified sites that differed from the reference genome (called here variants) and constructed empirical priors for the distribution of variant frequencies in each sample independently. We obtained high-credibility intervals (posterior probability $ 1 -10 25 ) for the observed frequency of the variants using the statistical algorithm for variant identification (SAVI) algorithm 37, 38 . Variants were considered absent if found with a frequency between 0 and 2%, and were considered present if detected with a frequency above 15%. We chose 15% as a cut-off given its correspondence with the sensitivity threshold of direct Sanger sequencing. Variant total depth was required to be .103 and ,3003. Segmenting variants that exist in one case only and absent in the other five cases identified regions of possible copy number aberrations. We removed the variants found in these regions. We also excluded all silent variants and those present in the dbSNP database, and focused only on substitution mutations. Finally, in the tumour samples, we removed all variants found present in any of the normal samples.
The mutations were subjected to validation (present in tumour, absent in normal) by conventional Sanger-based resequencing analysis of PCR products obtained from tumour DNA using primers specific for the exon encompassing the variant. Data were deposited in the Sequence Read Archive (accession number SRP031981). Microarray analysis. Total RNA was extracted from primary osteoblasts isolated from mouse calvaria using TRIzol reagent (Invitrogen). Microarray analysis was performed using the GeneChip 39 IVT Express kit and mouse genome 430 2.0 array gene chips (Affymetrix) according to the manufacturer's instructions. In brief, antisense RNA was synthesized from 500 ng of RNA and was biotinylated followed by purification and fragmentation using the GeneChip 39 IVT Express kit. Fragmented aRNA was hybridized to Affymetrix mouse genome 430 2.0 array gene chips. Following hybridization, chips were scanned with a GeneChip Scanner 3000 7G (Affymetrix). Data were normalized using the Mas5 method 39 , and then log 2 transformed. Data were deposited in Gene Expression Omnibus (accession number GSE43242) 40 , Differential expression was analysed using LIMMA 41 . We focused on about 20 genes which we selected in advance of the analysis. Genes were considered which either are active in AML, are amplified according to our CGH results, activate Notch, or whose transcription is induced by Notch. A significance cutoff of a raw P , 0.05 was used, as is appropriate for small previously determined gene sets 42 . Representative probe sets of genes whose expression changed greater than 6 20% in at least one of the two mutants relative to wild type appear in Supplementary Table 1 . Bone marrow transplantation. For bone marrow transplantation studies, adult wild-type B5.SJL (CD45.1) recipient mice (8 weeks of age) were lethally irradiated (10 Gy, split dose) and were then transplanted with 1 3 10 5 of total bone marrow cells from Ctnnb1 CAosb (CD45.2) or wild-type B5.SJL (CD45.2) mice (4 weeks of age) by retro-orbital venous plexus injection. Engraftment efficiency in recipients was monitored by donor contribution of CD45.2 1 cells using FACS analysis. For the reverse experiment, because of the early lethality of Ctnnb1 CAosb mice, 1 3 10 5 of total bone marrow cells from wild-type B6.SJL (CD45.1) mice were transplanted into lethally irradiated (600 rads, split dose) newborn (P1) Ctnnb1 CAosb mice or wild-type littermates by liver injections. Engraftment efficiency in recipients was monitored by donor contribution of CD45.1 1 cells using FACS analysis. For HSC and progenitor transplantation studies, sublethally (5.5 Gy) irradiated wild-type B5.SJL (CD45.1) recipient mice (8 weeks of age) were injected with fractionated donor bone marrow subsets isolated from Ctnnb1 CAosb (CD45.2) or wild-type B5.SJL (CD45.2) mice (4 weeks of age). Engraftment efficiency in recipients was monitored by donor contribution of CD45.2 1 cells using FACS analysis. Treatment of animals with c-secretase inhibitor. Two-week-old Ctnnb1 CAosb mice or their wild-type littermates were treated with vehicle, the c-secretase inhibitor DBZ ((2S)-2-[2-(3,5-difluorophenyl)-acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,-d]azepin-7-yl)-propionamide, 2 mmol kg 21 ) daily by intraperitoneal injection for 10 days. DBZ is cell-permeable, selective, non-transition and non-competitive inhibitor of the c-secretase complex. DBZ was synthesized to .99.9% purity as assessed by liquid chromatography/mass spectrometry (LC/ MS) (Syncom) and suspended in a 0.5% methocel E4M (w/v, Colorcon) and 0.1% (v/v) Tween-80 (Sigma) solution 43 . Immediately before intraperitoneal injection, DBZ was sonicated for 2 min to achieve a homogenous suspension. Haematological measurements and peripheral blood morphology. For haematological measurements, blood was collected by cardiac puncture. Peripheral blood cell counts were performed on a FORCYTE haematology analyser (Oxford Science). For morphological assessment, peripheral blood smears were stained with Wright-Giemsa stain (Sigma-Aldrich) for 10 min followed by rinsing in dH 2 O for 3 min. Images were taken using a 603 objective on a Leica microscope outfitted with a camera. Real-time PCR. Total RNA was isolated from LSK or haematopoietic cells using RNeasy Micro Plus kit (Qiagen). Total RNA from bone marrow-free long bones was isolated using TRIzol reagent after removal of the periosteal layer. Quantitative real-time PCR was performed using the SYBR Green Master Mix (Bio-Rad) as previously described 32 . b-actin was used as endogenous control. Gene expression in LT-HSCs, ST-HSCs and MPPs was performed using the Power SYBR Green Cells-to-CT kit (Ambion Life Technologies). Reporter constructs and luciferase assays. The Jag1 promoter region carries multiple potential TCF/LEF binding sites (C/TCTTTG) located up to nucleotide 24075 (24075, 23072, 22626, 22578, 22343, 21992, 21957, 21566, 21221, 2782) . The mouse reporter constructs 24112/1130 and 22100/1130 for Jag1-luc were generated by PCR amplification of the corresponding fragments using mouse genomic DNA as template and subsequent subcloning into the BglII and KpnI/ BglII sites of the pGL3Basic vector (Promega), respectively. Transient transfection m, Extramedullar haematopoiesis in the liver of 3-weeks-old Ctnnb1 CAosb mice indicated by megakaryocytes (black arrow), myeloid (white arrow) and rare erythroid precursors (dotted arrow). n-p Percentage of Ter119 1 (n), CD11b 1 /Gr1 1 (o) and myeloid progenitor (p) populations in the spleen. q, PCR analysis of genomic DNA from osteoblasts and indicated haematopoieic populations from wild-type and Ctnnb1 CAosb mice. r-t, Real-time PCR analysis of b-catenin targets in bone marrow CD45 1 CD34 1 CD31 1 cells (r), spleen (s) and bones (t). In a, n 5 6; b-k, n-p, n 5 8; l, m, n 5 5 and r-t, n 5 4 mice per group. Results are mean 6 s.d. and show a representative from five (a-p) or 2 (q-t) independent experiments. *P , 0.05 versus wild type. MNC, mononuclear cells. i-l, B-cell progenitors numbers in the bone marrow (i, j), spleen (k) and lymph nodes (l). m-t, Proportion of T cells. u, Lack of myeloid cell differentiation in Ctnnb1 CAosb bone marrow cells following treatment with cytokines. v-x, Percentage of immature myeloid cells in ex vivo bone marrow cultures treated with cytokines. y, Robertsonian translocation between chromosomes 1 and 19 in 2 of 30 metaphases of the spleen of an 18-day-old Ctnnb1 CAosb mouse. Inset shows the same abnormality in another cell. z, Whole-exome sequencing of myeloid malignancies (CD11b 1 /Gr1 1 ) from 3 Ctnnb1 CAosb mice and 3 germline normal (tail) samples. In i-x, n 5 6 mice per group. *P , 0.05 versus wild type. Results are mean 6 s.d. and show a representative of five (i-t) or three (u-x) independent experiments.
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